8-K

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the

Securities Exchange Act of 1934

Date of Report (date of earliest event reported): May 8, 2014

MEDNAX, INC.

(Exact Name of Registrant as Specified in Its Charter)

 

Florida

 

001-12111

 

26-3667538

(State or Other Jurisdiction of

Incorporation)

 

(Commission File

Number)

  (IRS Employer Identification No.)

1301 Concord Terrace

                                 Sunrise, Florida 33323                                

(Address of principal executive office) (zip code)

Registrant’s telephone number, including area code (954) 384-0175

 

 

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

¨ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

¨ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

¨ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

¨ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

 

 


Item 5.07 Submission of Matters to a Vote of Security Holders.

On May 8, 2014, MEDNAX, Inc., a Florida corporation (the “Company”), held its 2014 Annual Shareholders’ Meeting (the “Annual Meeting”). Of the 100,199,859 shares of common stock outstanding and entitled to vote, 90,522,627 shares were represented, constituting a quorum. The final results for each of the matters submitted to a vote of shareholders at the Annual Meeting are as follows:

Proposal 1: All of the Board’s nominees for Director were elected to serve until the Company’s 2015 Annual Shareholders’ Meeting or until their respective successors are elected and qualified, by the votes set forth in the table below:

 

Name

   For      Withheld      Broker
Non-Vote
 

Cesar L. Alvarez

     70,395,459         16,370,025         3,757,143   

Waldemar A. Carlo, M.D.

     75,661,374         11,104,110         3,757,143   

Michael B. Fernandez

     73,507,684         13,257,800         3,757,143   

Roger K. Freeman, M.D.

     84,024,403         2,741,081         3,757,143   

Paul G. Gabos

     84,581,113         2,184,371         3,757,143   

Pascal J. Goldschmidt, M.D.

     86,310,123         455,361         3,757,143   

Manuel Kadre

     78,063,220         8,702,264         3,757,143   

Roger J. Medel, M.D.

     84,876,149         1,889,335         3,757,143   

Donna E. Shalala, Ph.D.

     86,730,686         34,798         3,757,143   

Enrique J. Sosa, Ph.D.

     86,471,707         293,777         3,757,143   

Proposal 2: The appointment of PricewaterhouseCoopers LLP as the Company’s independent registered certified public accounting firm for the 2014 fiscal year was ratified by the shareholders, by the votes set forth in the table below:

 

For

 

Against

 

Abstained

 

Broker

Non-Vote

88,085,579

  2,404,594   32,454   0


Proposal 3: The shareholders approved, on a non-binding, advisory basis, the compensation of the Company’s named executive officers, by the votes set forth in the table below:

 

For

 

Against

 

Abstained

 

Broker

Non-Vote

70,256,610

  15,405,947   1,102,927   3,757,143


SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

    MEDNAX, INC.

Date: May 8, 2014

    By:   /s/ Vivian Lopez-Blanco
      Vivian Lopez-Blanco
      Chief Financial Officer